- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate-To-Severe Asthma — Recruiting • Phase II • Respiratory / COPD / Asthma • NCT06977581.
- Treatment being tested: PF-07275315, an investigational medicine for moderate-to-severe asthma, with assessment of its safety profile and clinical efficacy in reducing breathing difficulties.
- Patient eligibility: Adults with confirmed moderate-to-severe asthma diagnosis; typically requires documented airway obstruction, suboptimal control on current therapy, and absence of significant comorbidities that would compromise trial safety.
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
The purpose of this clinical trial is to learn about the safety and effects of the study medicine (called PF-07275315) for the potential treatment of moderate-to-severe asthma. Asthma is a condition that makes it challenging to breathe, which negatively impacts the quality of life and functioning of people who are affected. This study is seeking participants who: * Are 18 to 70 years old * Have had moderate-to-severe asthma for at least 12 months that is not well controlled * Have been taking their regular maintenance treatment(s) for asthma over…
- : Must meet the following asthma criteria: 1. History of persistent, moderate-to-severe asthma for at least 12 months prior to screening. 2. Must have experienced at least 1 asthma exacerbation requiring treatment with systemic steroids (oral or parenteral) for 3 days or more within 12 months of the screening visit. 3. At least 2 of the 3 pre-bronchodilator FEV1 values collected in the run-in period and the mean of the of pre-bronchodilator FEV1 values collected in the run-in period are ≥30% to
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.